enGene Therapeutics Inc(ENGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.08 | Insider Own | 57.56% | Shs Outstand | 67.0M | Perf Week | -1.92% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 17.38% | Insider Trans | 0.01% | Shs Float | 28.4M | Perf Month | -22.73% |
| Enterprise Value | -0.13B | PEG | - | EPS next Q | -0.46 | Inst Own | 42.88% | Short Float | 5.28% | Perf Quarter | -13.56% |
| Income | -0.13B | P/S | - | EPS this Y | 20.83% | Inst Trans | -21.1% | Short Ratio | 2.02 | Perf Half Y | -78.9% |
| Sales | 0.00B | P/B | 0.45 | EPS next 5Y | 23.88% | ROA | -48.84% | Short Interest | 1.50M | Perf YTD | -83.06% |
| Book/sh | 3.44 | P/C | 0.38 | EPS past 3/5Y | - -255.92% | ROE | -60.5% | 52W High | -87.51% ($12.25) | Perf Year | -78.02% |
| Cash/sh | 3.98 | P/FCF | - | Sales past 3/5Y | - | ROIC | -49.92% | 52W Low | 9.29% ($1.40) | Perf 3Y | -93.22% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -9.75% | Gross Margin | - | Volatility(W/M) | 4.5% 5.48% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.21 | EPS Q/Q | 17.85% | Profit Margin | - | RSI (14) | 37.04 | Recom | 2.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.21 | Sales Q/Q | - | SMA20 | -7.23% ($1.65) | Beta | -0.28 | Target Price | $3.5 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/9/8 | SMA50 | -14.93% ($1.8) | Rel Volume | 1.58 | Prev Close | $1.53 |
| Employees | 82 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | -10.17% - | SMA200 | -64.98% ($4.37) | Avg Volume(3M) | 0.74M | Price | $1.53 |
| IPO | 2022/2/1 | Option/Short | Yes/Yes | Trades | 2048 | Volume | 1,177,648 | Change | - |
🧬 Engine Therapeutics is a clinical-stage biotech developing non-viral gene therapies. Centered on a lead candidate targeting non-muscle invasive bladder cancer (NMIBC) confined to the bladder lining, it is a drug developer pursuing a therapeutic approach that acts directly on the targeted tumor area, based on its proprietary gene delivery technology that does not rely on viral vectors.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded more than usual. That is 158% of its average volume.
ENGN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.8% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -93.2%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 42.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
BBC Virtus Biotech Clinical Trials ETF <0.01% 
AVSC Avantis U.S Small Cap Equity ETF <0.01% It ranks #350 of 595 in the industry
Based on market cap of $103M.
UNCY#348 Unicycive Therapeutics Inc $104M PER - 
TLSA#349 Tiziana Life Sciences Ltd $103M PER - ENGN#350 enGene Therapeutics Inc $103M PER - 
IMUX#351 Immunic Inc $102M PER - 
BDTX#352 Black Diamond Therapeutics Inc $102M PER - 
FAQ
What kind of company is ENGN?
ENGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENGN?
The market cap of ENGN is approximately $103M, ranking 4,444 within its sector.
What is the 52-week high and low for ENGN?
ENGN has recorded a 52-week high of $12.25 and a low of $1.40.
